End-of-day quote
Korea S.E.
03:30:00 07/06/2024 am IST
|
5-day change
|
1st Jan Change
|
9,800
KRW
|
-0.10%
|
|
-3.92%
|
-3.73%
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
73,024
|
5,05,923
|
1,07,379
|
2,02,956
|
1,95,380
|
-
|
Enterprise Value (EV)
2 |
73.02
|
517.8
|
107.4
|
203
|
202.8
|
186.4
|
P/E ratio
|
-6.63
x
|
-39.6
x
|
-7.88
x
|
-
|
21.3
x
|
10.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
27.3
x
|
-
|
6.79
x
|
3.19
x
|
2.07
x
|
EV / Revenue
|
-
|
27.9
x
|
-
|
6.79
x
|
3.31
x
|
1.97
x
|
EV / EBITDA
|
-
|
-815
x
|
-
|
-
|
13.8
x
|
6.68
x
|
EV / FCF
|
-
|
-190
x
|
-
|
-59.4
x
|
29.4
x
|
16.1
x
|
FCF Yield
|
-
|
-0.53%
|
-
|
-1.68%
|
3.4%
|
6.22%
|
Price to Book
|
-
|
9.68
x
|
-
|
-
|
8.18
x
|
4.51
x
|
Nbr of stocks (in thousands)
|
10,417
|
12,906
|
13,406
|
19,937
|
19,937
|
-
|
Reference price
3 |
7,010
|
39,200
|
8,010
|
10,180
|
9,800
|
9,800
|
Announcement Date
|
30/03/20
|
24/02/21
|
16/03/23
|
12/03/24
|
-
|
-
|
1KRW in Million2KRW in Billions3KRW Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
18.54
|
-
|
29.9
|
61.2
|
94.5
|
EBITDA
1 |
-
|
-0.6351
|
-
|
-
|
14.7
|
27.9
|
EBIT
1 |
-
|
-3.716
|
-
|
2.034
|
12.3
|
25.4
|
Operating Margin
|
-
|
-20.05%
|
-
|
6.8%
|
20.1%
|
26.88%
|
Earnings before Tax (EBT)
1 |
-
|
-10.07
|
-
|
-6.517
|
11.9
|
26
|
Net income
1 |
-11.03
|
-11.76
|
-13.63
|
-5.289
|
9.2
|
19.4
|
Net margin
|
-
|
-63.44%
|
-
|
-17.68%
|
15.03%
|
20.53%
|
EPS
2 |
-1,058
|
-989.0
|
-1,017
|
-
|
460.0
|
975.0
|
Free Cash Flow
3 |
-
|
-2,721
|
-
|
-3,417
|
6,900
|
11,600
|
FCF margin
|
-
|
-14,678.01%
|
-
|
-11,427.44%
|
11,274.51%
|
12,275.13%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
46,938.78%
|
41,577.06%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
75,000%
|
59,793.81%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
24/02/21
|
16/03/23
|
12/03/24
|
-
|
-
|
1KRW in Billions2KRW3KRW in Million Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
11.9
|
-
|
-
|
7.4
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
9
|
Leverage (Debt/EBITDA)
|
-
|
-18.72
x
|
-
|
-
|
0.5034
x
|
-
|
Free Cash Flow
2 |
-
|
-2,721
|
-
|
-3,417
|
6,900
|
11,600
|
ROE (net income / shareholders' equity)
|
-
|
-20.6%
|
-
|
-25.6%
|
47.6%
|
57.9%
|
ROA (Net income/ Total Assets)
|
-
|
-10.2%
|
-
|
-
|
17.3%
|
28.8%
|
Assets
1 |
-
|
115
|
-
|
-
|
53.18
|
67.36
|
Book Value Per Share
3 |
-
|
4,048
|
-
|
-
|
1,198
|
2,173
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.94
|
-
|
2.05
|
2.8
|
3.4
|
Capex / Sales
|
-
|
10.49%
|
-
|
6.85%
|
4.58%
|
3.6%
|
Announcement Date
|
30/03/20
|
24/02/21
|
16/03/23
|
12/03/24
|
-
|
-
|
1KRW in Billions2KRW in Million3KRW |
1st Jan change
|
Capi.
|
---|
| -3.73% | 143M | | -3.76% | 11.53B | | -4.86% | 8.33B | | +43.30% | 5.74B | | -22.44% | 4.65B | | +7.79% | 3.42B | | -17.26% | 2.63B | | -13.36% | 2.05B | | -16.39% | 1.9B | | -31.24% | 1.59B |
Medical Devices & Implants
|